Marc M. Gibeley serves as Independent Director of the Company. Mr. Gibeley has served as Chief Executive Officer of Nutritional Medicinals, LLC, a producer of organic whole food feeding tube formulas and meal replacements, since November 2018. Prior to that, Mr. Gibeley served as Chief Executive Officer and Director of Scientific Intake Ltd. Co., a medical device and digital healthcare company focused on weight management and the prevention of obesity related chronic diseases, from October 2016 to January 2018. Prior to that, Mr. Gibeley served as Head of Diabetes Care North America for Roche Holding AG (SIX: RO), a leading research-focused pharmaceuticals and diagnostics healthcare company from 2011 through 2016. Mr. Gibeley served as the President and Chief Executive Officer of WaveRx, a venture-backed diabetes neuropathy medical device company, from 2008 through 2011. Prior to joining WaveRx, Mr. Gibeley worked for several consumer packaged goods companies, including Procter & Gamble (NYSE: PG), Eastman Kodak (NYSE: KODK) and Kraft Foods (NASDAQ: KHC).
As the Independent Director of Invacare, the total compensation of Marc Gibeley at Invacare is $240,270. There are 13 executives at Invacare getting paid more, with Matthew Monaghan having the highest compensation of $8,340,920.
Marc Gibeley is 55, he's been the Independent Director of Invacare since 2015. There are 11 older and 6 younger executives at Invacare. The oldest executive at Invacare Corp. is Susan Alexander, 63, who is the Independent Director.
Marc's mailing address filed with the SEC is ONE INVACARE WAY, , ELYRIA, OH, 44035.
Over the last 21 years, insiders at Invacare have traded over $3,551,958 worth of Invacare stock and bought 391,450 units worth $2,325,949 . The most active insiders traders include Edward F Crawford, Aaron Malachi Iii Mixon és Steven H Azurite Management.... On average, Invacare executives and independent directors trade stock every 52 days with the average trade being worth of $10,700. The most recent stock trade was executed by Steven H Azurite Management... on 17 November 2022, trading 122,820 units of IVC stock currently worth $47,900.
Invacare Corporation is a leading manufacturer and distributor in its markets for medical equipment used in non-acute care settings. At its core, the Company designs, manufactures, and distributes medical devices that help people to move, breathe, rest and perform essential hygiene. The Company provides clinically complex medical device solutions for congenital (e.g., cerebral palsy, muscular dystrophy, spina bifida), acquired (e.g., stroke, spinal cord injury, traumatic brain injury, post-acute recovery, pressure ulcers) and degenerative (e.g., ALS, multiple sclerosis, chronic obstructive pulmonary disease (COPD), elderly, bariatric) ailments. The Company's products are important parts of care for people with a wide range of challenges, from those who are active and involved in work or school each day and may need additional mobility or respiratory support, to those who are cared for in residential care settings, at home and in rehabilitation centers. The Company sells its products principally to home medical equipment providers with retail and e-commerce channels, residential care operators, distributors and government health services in North America, Europe and Asia Pacific.
Invacare executives and other stock owners filed with the SEC include: